Breaking News Instant updates and real-time market news.

AMRN

Amarin

$3.19

0.03 (0.95%)

06:06
09/13/17
09/13
06:06
09/13/17
06:06

Amarin raises FY17 U.S product revenue view to $165-$175 from $155M-165M

Consensus for FY17 revenue is $172.9M.

  • 25

    Sep

AMRN Amarin
$3.19

0.03 (0.95%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/17
06/29/17
NO CHANGE
Target $7

Buy
Jefferies boosts Amarin target to $7 ahead of mid-2018 data
Jefferies analyst Matthew Andrews views Amarin's risk/reward as favorable into the Vascepa mixed dyslipidemia data in mid-2018. Positive data could support a "paradigm shift" in treating the 70M mixed dyslipidemia patients with high trigylcerides and lead to broader Vascepa use, Andrews tells investors in a research note. The analyst assigns a 55% probability of positive REDUCE-IT trial data and models $1.3B in peak-adjusted sales. He sees a floor of $2 per share with negative data and long-term upside to $17 per share over the long-term with positive data. The analyst boosted his price target for Amarin shares to $7 from $5 and keeps a Buy rating on the name. The stock closed yesterday at $3.78.
08/03/17
HCWC
08/03/17
NO CHANGE
Target $10
HCWC
Buy
Amarin valuation attractive into interim data, says H.C. Wainwright
Amarin's current valuation is supported by the "strong" underlying Vascepa sales alone, H.C. Wainwright analyst Andrew Fein tells investors in a post-earnings research note. He believes the recent share pullback provides an opportunity for a "free shot" at the upcoming interim look of the REDUCE-IT trial. Investors are ascribing no value to the interim nor full study at all, the analyst contends. He reiterates a Buy rating on Amarin with a $10 price target.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

, KORS

Michael Kors

09:40
09/19/17
09/19
09:40
09/19/17
09:40
Options
Unusually active option classes on open September 19th »

Unusual total active…

KSU

Kansas City Southern

KORS

Michael Kors

AAOI

Applied Optoelectronics

$66.29

7.99 (13.71%)

RAD

Rite Aid

NKE

Nike

M

Macy's

EFX

Equifax

INTC

Intel

VIX

Volatility Index S&P 500 Options

AMD

AMD

$13.08

0.56 (4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 23

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 28

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 16

    Nov

NKE

Nike

09:37
09/19/17
09/19
09:37
09/19/17
09:37
Recommendations
Nike analyst commentary  »

Nike risk/reward remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

SMBK

SmartFinancial

$23.88

0.38 (1.62%)

09:36
09/19/17
09/19
09:36
09/19/17
09:36
Hot Stocks
SmartFinancial, Capstone Bancshares holders approve merger-related proposals »

SmartFinancial and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
09/19/17
09/19
09:35
09/19/17
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD edged…

PG

Procter & Gamble

09:34
09/19/17
09/19
09:34
09/19/17
09:34
Hot Stocks
Peltz says Procter & Gamble should have bought Method Soap »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CORI

Corium

$10.16

0.25 (2.52%)

, NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

09:33
09/19/17
09/19
09:33
09/19/17
09:33
Conference/Events
Mizuho to hold a conference »

Biotechnology CNS Deep…

CORI

Corium

$10.16

0.25 (2.52%)

NEOS

Neos Therapeutics

$8.70

-0.5 (-5.43%)

VYGR

Voyager Therapeutics

$17.36

1.01 (6.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

NVAX

Novavax

$1.12

-0.02 (-1.75%)

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Hot Stocks
Novavax initiates Phase 1/2 trial of NanoFlu vaccine in older adults »

Novavax announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BSMX

Santander Mexico

09:32
09/19/17
09/19
09:32
09/19/17
09:32
Downgrade
Santander Mexico rating change  »

Santander Mexico…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPLR

Xplore Technologies

$3.50

-0.2 (-5.41%)

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Hot Stocks
Xplore Technologies secures Android rugged tablet order »

Xplore Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 30

    Nov

SNE

Sony

09:31
09/19/17
09/19
09:31
09/19/17
09:31
Downgrade
Sony rating change  »

Sony downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
09/19/17
09/19
09:30
09/19/17
09:30
General news
The U.S. August housing starts report »

The U.S. August housing…

BSX

Boston Scientific

09:29
09/19/17
09/19
09:29
09/19/17
09:29
Hot Stocks
Boston Scientific's HeartLogic Diagnostic shows positive risk detection ability »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:28
09/19/17
09/19
09:28
09/19/17
09:28
Hot Stocks
Ubiquiti CEO to host Investor Update on September 26 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

HQY

HealthEquity

$45.77

0.65 (1.44%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Conference/Events
HealthEquity participates in a conference call with Chardan »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:26
09/19/17
09/19
09:26
09/19/17
09:26
Hot Stocks
Ubiquiti Board approves additional $100M stock repurchase program »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

09:23
09/19/17
09/19
09:23
09/19/17
09:23
Earnings
Ubiquiti narrows Q1 revenue view to $240M-$250M, consensus $234.5M »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LNDC

Landec

$12.80

-0.2 (-1.54%)

09:22
09/19/17
09/19
09:22
09/19/17
09:22
Hot Stocks
Landec provides update on impact from extreme weather events »

Landec provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BOBE

Bob Evans

$72.93

1.02 (1.42%)

, POST

Post Holdings

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Bob Evans (BOBE),…

BOBE

Bob Evans

$72.93

1.02 (1.42%)

POST

Post Holdings

AZO

AutoZone

TLGT

Teligent

$6.90

-0.29 (-4.03%)

WBA

Walgreens Boots Alliance

$82.60

0.1 (0.12%)

RAD

Rite Aid

APOG

Apogee Enterprises

$44.98

0.18 (0.40%)

EFX

Equifax

ALDX

Aldeyra

$9.10

0.2 (2.25%)

SNCR

Synchronoss

$16.75

0.64 (3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 30

    Oct

  • 19

    Sep

PG

Procter & Gamble

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Hot Stocks
Peltz says not asking for P&G CEO David Taylor to step down »

Nelson Peltz of Trian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOX

Amdocs

$64.13

1.64 (2.62%)

09:19
09/19/17
09/19
09:19
09/19/17
09:19
Conference/Events
Amdocs participates in a conference call with Oppenheimer »

Conference call for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYL

Tyler Technologies

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Hot Stocks
Tyler Technologies selected by Odessa, Texas for ERP solution »

Tyler Technologies signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
09/19/17
09/19
09:18
09/19/17
09:18
Options
Overnight activity included 97 trades in SPX and 67 trades in VIX »

97 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APD

Air Products

09:16
09/19/17
09/19
09:16
09/19/17
09:16
Hot Stocks
Air Products awarded oxygen supply contract by South Korean chemical company »

Air Products has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

, XYL

Xylem

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Conference/Events
Cowen to hold a summit »

Industrial Innovation…

TPIC

TPI Composites

$20.98

-0.05 (-0.24%)

XYL

Xylem

WLDN

Willdan Group

$29.79

0.71 (2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 28

    Sep

MDLZ

Mondelez

$40.71

-0.15 (-0.37%)

, PG

Procter & Gamble

09:15
09/19/17
09/19
09:15
09/19/17
09:15
Hot Stocks
Peltz says Mondelez price raises were due to higher cocoa prices »

Nelson Peltz of Trian is…

MDLZ

Mondelez

$40.71

-0.15 (-0.37%)

PG

Procter & Gamble

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.